AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval

Long Wait For First Tremelimumab Approval Could Soon Be Over

 
• By Andrew McConaghie

AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.

Astrazeneca
AstraZeneca could gain its first approval for the immunotherapy combination by the end of 2022 - but rivals Roche have a head start in liver cancer. • Source: Alamy

More from Business

More from Scrip